Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRL advanced for three days, in 200 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CRL as a result. In 55 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for CRL just turned positive on October 20, 2026. Looking at past instances where CRL's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 145 of 228 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
CRL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 2 (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.798) is normal, around the industry mean (64.450). P/E Ratio (-71.699) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for CTSO turned positive on October 08, 2026. Looking at past instances where CTSO's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on CTSO as a result. In 84 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +7.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTSO advanced for three days, in 191 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for CTSO crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTSO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CTSO broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTSO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CTSO's P/B Ratio (-22.448) is slightly lower than the industry average of (2.923). P/E Ratio (-0.922) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.483) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CTSO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTSO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CRL | CTSO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 100 | |
PRICE GROWTH RATING 1..100 | 2 | 84 | |
P/E GROWTH RATING 1..100 | 85 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRL's Valuation (15) in the Miscellaneous Commercial Services industry is in the same range as CTSO (23) in the Medical Specialties industry. This means that CRL’s stock grew similarly to CTSO’s over the last 12 months.
CRL's Profit vs Risk Rating (100) in the Miscellaneous Commercial Services industry is in the same range as CTSO (100) in the Medical Specialties industry. This means that CRL’s stock grew similarly to CTSO’s over the last 12 months.
CRL's SMR Rating (93) in the Miscellaneous Commercial Services industry is in the same range as CTSO (100) in the Medical Specialties industry. This means that CRL’s stock grew similarly to CTSO’s over the last 12 months.
CRL's Price Growth Rating (2) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CTSO (84) in the Medical Specialties industry. This means that CRL’s stock grew significantly faster than CTSO’s over the last 12 months.
CRL's P/E Growth Rating (85) in the Miscellaneous Commercial Services industry is in the same range as CTSO (100) in the Medical Specialties industry. This means that CRL’s stock grew similarly to CTSO’s over the last 12 months.
| CRL | CTSO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | N/A |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 68% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 70% | 2 days ago 78% |
| Declines ODDS (%) | 4 days ago 70% | 8 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 2 FA rating(s) are green while CTSO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 4 TA indicator(s) are bullish while CTSO’s TA Score has 3 bullish TA indicator(s).
CRL (@Medical Specialties) experienced а +14.20% price change this week, while CTSO (@Medical/Nursing Services) price change was +77.74% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.66%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +41.88%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.58%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -10.51%.
CRL is expected to report earnings on Nov 04, 2026.
CTSO is expected to report earnings on Nov 12, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.58% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To CRL | 1D Price Change % | ||
|---|---|---|---|---|
| CRL | 100% | +9.33% | ||
| IQV - CRL | 71% Closely correlated | +3.28% | ||
| RGEN - CRL | 56% Loosely correlated | +0.63% | ||
| AZTA - CRL | 56% Loosely correlated | +2.88% | ||
| MEDP - CRL | 56% Loosely correlated | +6.43% | ||
| BRKR - CRL | 53% Loosely correlated | +5.68% | ||
More | ||||
A.I.dvisor tells us that CTSO and TMDX have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CTSO and TMDX's prices will move in lockstep.
| Ticker / NAME | Correlation To CTSO | 1D Price Change % | ||
|---|---|---|---|---|
| CTSO | 100% | +0.56% | ||
| TMDX - CTSO | 25% Poorly correlated | -3.14% | ||
| LUNG - CTSO | 25% Poorly correlated | +0.55% | ||
| AZTA - CTSO | 23% Poorly correlated | +2.88% | ||
| CSTL - CTSO | 23% Poorly correlated | +3.68% | ||
| CRL - CTSO | 23% Poorly correlated | +9.33% | ||
More | ||||